Tolebrutinib did not show superiority over Aubagio (teriflunomide) in reducing relapse rates or MRI-detected inflammatory ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved ...

"Without that [Agency for Healthcare Research and Quality] support, we will become ineffective." -- former U.S. Preventive ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Gavin Giovannoni, MD, PhD, of Queen Mary University in London, discussing the HERCULES and GEMINI trials of investigational tolebrutinib in multiple sclerosis. "No one really knows quite what to do." ...